U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07870746) titled 'Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC' on Oct. 06.
Brief Summary: Multicenter Phase 2A study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC). Part 1 will evaluate two dosing regimens to determine the recommended Phase 3 dose (RP3D).
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
ccRCC
Renal Cell Carcinoma (Kidney Cancer)
Renal Cell Carcinoma (RCC)
Renal Cell Cancer Metastatic
Renal Cell Cancer, Recurrent
Clear Cell Renal Cell Cancer (ccRCC)
Interve...